Modus' CEO John Öhd and CFO Claes Lindblad will be interviewed by Aktier Live Sessions Jonathan Furelid on Tuesday, December 14 at 18:00. The interview is streamed live with the opportunity to ask questions to the company directly in the chat. The company tells of an eventful year during which, among other things, the company was listed on the Nasdaq First North Growth market and started the first clinical study in the planned sepsis program.

Follow any of the links below to follow the live broadcast.

Facebook live event: https://fb.me/e/1bdmcxJkk

Youtube: https://www.youtube.com/watch?v=F_McJUQvlxI

Linkedin Live: https://www.linkedin.com/video/event/urn:li:ugcPost:6873798298520571904/

For more information on Modus Therapeutics, please contact:

John Öhd, VD, Modus Therapeutics

Telefon: +46 (0) 70 766 80 97

E-post: john.ohd@modustx.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se

About Modus Therapeutics and sevuparin

Modus Therapeutics is a Swedish biotechnology company headquartered in Stockholm that develops sevuparin with a focus on diseases with a high unmet medical need. The company's focus in the near future is to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at www.modustx.com

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregate effects.  Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.